When primary liver cancer is associated with ascites, jaundice, distant metastasis, etc., it is called advanced primary liver cancer. The treatment of advanced primary liver cancer is difficult, and the clinical treatment effect is not ideal. Surgery is not an option for treating advanced liver cancer because it has spread to lymph nodes or other organs.
If the liver is in good condition (Child-Pugh grade A or B), the doctor will consider treatment with the targeted therapeutic drugs Sorafenib (Nexavar) or Lenvama (Lenvima). Growth can prolong the survival time of patients. If the patient develops drug resistance, the targeted drug repaglinide (Stivarga) or the immunotherapy drug nivolumab (Opdivo) can be used instead.
In addition, keeping an eye on clinical trial information at any time and actively participating in relevant clinical trials such as chemotherapy, radiotherapy, and immunotherapy may also bring opportunities and hope for patients with advanced liver cancer. It is hoped that in the next few years, researchers will make a huge breakthrough in the field of liver cancer diagnosis and treatment.
